双镜像疗法对卒中后失语命名恢复的疗效:一项随机对照试验
结果显示两组CRRCAE命名评分均显著改善(P<0.001),DMTG改善幅度更大(t=2.689,P=0.011);DMTG在BDAE分级分布、显著改善率(45.00% vs. 10.53%)和总有效率(95.00% vs. 68.42%)上均显著优于CG。结论认为DMT安全性良好,可显著改善命名功能并降低失语严重程度。
要点
- 双镜像疗法联合言语训练较单纯言语训练更显著改善卒中后失语患者命名评分(P=0.011)。
- DMTG显著改善率45.00%、总有效率95.00%,均显著高于对照组的10.53%和68.42%。
- DMT安全性良好,未报告治疗相关不良事件。
核心结论
- 双镜像疗法可显著改善卒中后失语患者的命名功能并降低失语严重程度,安全性良好,可作为安全有效的辅助治疗。
主要发现
- 干预后两组CRRCAE命名评分均显著改善(P<0.001),DMTG改善幅度大于CG(t=2.689,P=0.011)。
- DMTG在BDAE分级分布上显著优于CG(χ²=5.718,P=0.017)。
- DMTG显著改善率为45.00%,CG为10.53%(χ²=5.718,P=0.017)。
- DMTG总有效率为95.00%,CG为68.42%(χ²=4.467,P=0.031)。
- DMT安全性良好,未报告治疗相关不良事件。
关键数值与推荐
- CRRCAE命名评分组间比较:t=2.689,P=0.011, favors DMTG。
- BDAE分级分布组间比较:χ²=5.718,P=0.017, favors DMTG。
- 显著改善率:DMTG 45.00% vs. CG 10.53%,χ²=5.718,P=0.017。
- 总有效率:DMTG 95.00% vs. CG 68.42%,χ²=4.467,P=0.031。
- 显著性水平设定为P<0.05。
临床怎么用
- 对卒中后手功能障碍伴表达性失语患者,可在常规言语训练基础上联合双镜像疗法以改善命名功能。
- 干预周期为4周,评估可采用CRRCAE和BDAE。
局限性
- 样本量较小(DMTG n=20,CG n=19),为单盲设计。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This single-blind, randomized controlled trial aims to observe the effect of Dual Mirror Therapy (DMT) on naming function in patients with post-stroke aphasia (PSA). DESIGN: Forty patients with post-stroke hand dysfunction and expressive aphasia were randomized to either a Dual Mirror Therapy group (DMTG, n=20) receiving combined DMT and conventional speech training, or a Control Group (CG, n=19) receiving speech training alone. Both groups completed the 4-week intervention. Naming ability and aphasia severity were assessed before and after using the Chinese Rehabilitation Research Center Aphasia Examination (CRRCAE) and the Boston Diagnostic Aphasia Examination (BDAE). Data were analyzed with t-tests, Chi-square, and rank-sum tests (significance at P<0.05). RESULTS: Following the intervention, CRRCAE naming scores improved significantly in both groups (P<0.001), with a greater increase observed in the DMTG versus the CG (t=2.689, P=0.011).Intergroup comparisons significantly favored the DMTG in: BDAE grade distribution (χ²=5.718, P=0.017), significant improvement rate (45.00% vs. 10.53%; χ² =5.718, P=0.017), and total effective rate (95.00% vs. 68.42%; χ²=4.467, P=0.031). CONCLUSION: DMT showed a good safety profile with no treatment-related adverse events. It significantly improves naming function and reduces aphasia severity in patients with PSA, presenting a safe and effective adjuvant therapy for aphasia.
引用
- Fu M, Xu S, Liang X, et al. Efficacy of Dual Mirror Therapy on Naming Recovery in Post-Stroke Aphasia: A Randomized Controlled Trial. Am J Phys Med Rehabil. 2026. PMID: 42155974. doi:10.1097/PHM.0000000000003019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。